Company intelligence / Profile preview

Xenome Ltd

Brisbane, Queensland, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Xenome’s lead product, Xen2174—a conopeptide analogue targeting NET—demonstrated safety and analgesic effect in a Phase I/II trial for cancer pain. The company’s platform leverages a proprietary library of over 2000 venom-derived peptides for drug discovery. Partnerships with MedImmune and Amylin validated the technology's potential. No recent clinical results are available after the late 2000s.

Therapeutic areas: OncologyRheumatologyMetabolic DisordersImmunology
Modalities: Peptide-based therapeuticsvenom-derived peptides
Industry: Biotech

Drug pipeline

1 asset

Xen2174

Discontinued

Partnerships

MedImmune/AstraZeneca – access to xdiscover™ library for drug discovery in key pain pathwaysAmylin Pharmaceuticals – joint research on metabolic/musculoskeletal targets using xdiscover™ platform

Beyond the preview

Go deeper on Xenome Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenome Ltd.

Explore the full profile